What are the big events to look for next year?

Novartis' ($NVS) Sandoz unit was the first to get a biosimilar approved in the U.S. with Zarxio, its copy of Amgen's ($AMGN) Neupogen, setting off what will be a significant development for the U.S. market as more copies of expensive biologics test the market. Many companies have built facilities with biosimilars in mind. But there were other significant events in 2015, huge M&A deals, and the ongoing uproar from consumers, payers, physicians and lawmakers over how drugmakers have been testing the limits drug pricing. Read about all of the most important developments of the year in FiercePharma. Report


Suggested Articles

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S. 

After months of delay for ultra-pricey gene therapy Zynteglo, Bluebird Bio is hoping to dose its first German patients in the first half of the year.

North Carolina is providing some financial assistance for the construction of Audentes gene therapy facility in Sanford, North Carolina. (Astellas)